GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rock Creek Pharmaceuticals Inc (OTCPK:RCPIQ) » Definitions » ROE %

Rock Creek Pharmaceuticals (Rock Creek Pharmaceuticals) ROE % : 0.00% (As of Jun. 2016)


View and export this data going back to 2015. Start your Free Trial

What is Rock Creek Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Rock Creek Pharmaceuticals's annualized net income for the quarter that ended in Jun. 2016 was $-11.18 Mil. Rock Creek Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Jun. 2016 was $-12.51 Mil. Therefore, Rock Creek Pharmaceuticals's annualized ROE % for the quarter that ended in Jun. 2016 was N/A%.

The historical rank and industry rank for Rock Creek Pharmaceuticals's ROE % or its related term are showing as below:

RCPIQ's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -44.08
* Ranked among companies with meaningful ROE % only.

Rock Creek Pharmaceuticals ROE % Historical Data

The historical data trend for Rock Creek Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rock Creek Pharmaceuticals ROE % Chart

Rock Creek Pharmaceuticals Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -378.93 -132.96 -205.45 - -

Rock Creek Pharmaceuticals Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rock Creek Pharmaceuticals's ROE %

For the Biotechnology subindustry, Rock Creek Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rock Creek Pharmaceuticals's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rock Creek Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Rock Creek Pharmaceuticals's ROE % falls into.



Rock Creek Pharmaceuticals ROE % Calculation

Rock Creek Pharmaceuticals's annualized ROE % for the fiscal year that ended in Dec. 2015 is calculated as

ROE %=Net Income (A: Dec. 2015 )/( (Total Stockholders Equity (A: Dec. 2014 )+Total Stockholders Equity (A: Dec. 2015 ))/ count )
=-6.845/( (-10.835+-10.646)/ 2 )
=-6.845/-10.7405
=N/A %

Rock Creek Pharmaceuticals's annualized ROE % for the quarter that ended in Jun. 2016 is calculated as

ROE %=Net Income (Q: Jun. 2016 )/( (Total Stockholders Equity (Q: Mar. 2016 )+Total Stockholders Equity (Q: Jun. 2016 ))/ count )
=-11.176/( (-12.026+-12.989)/ 2 )
=-11.176/-12.5075
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2016) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Rock Creek Pharmaceuticals  (OTCPK:RCPIQ) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2016 )
=Net Income/Total Stockholders Equity
=-11.176/-12.5075
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-11.176 / 0)*(0 / 12.878)*(12.878 / -12.5075)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2016 )
=Net Income/Total Stockholders Equity
=-11.176/-12.5075
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-11.176 / -11.18) * (-11.18 / -8.092) * (-8.092 / 0) * (0 / 12.878) * (12.878 / -12.5075)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9996 * 1.3816 * N/A % * 0 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Jun. 2016) net income data. The Revenue data used here is four times the quarterly (Jun. 2016) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Rock Creek Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Rock Creek Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rock Creek Pharmaceuticals (Rock Creek Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
2040 Whitfield Avenue, Suite 300, Sarasota, FL, USA, 34243
Rock Creek Pharmaceuticals Inc is engaged in research, development, and commercialization of therapies for chronic inflammatory disease and neurologic disorders, utilizing its proprietary compounds. The company is focusing its drug development efforts on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its proprietary formulations of its lead compound anatabine citrate. Its objective is to develop, obtain approval for, and commercialize pharmaceutical products utilizing its anatabine-based and related compounds.
Executives
Lee M Canaan director 20101 HOOVER RD, DETROIT MI 48205
Naomi Whittel director C/O STAR SCIENTIFIC, INC., 4470 COX ROAD, SUITE 110, GLEN ALLEN VA 23060
Ralph B Everett director 1299 PENNSYLVANIA AVE NW, 10TH FL, WASHINGTON DC 20004-2400
Richard L Sharp director C/O CIRCUIT CITY STORES, 9950 MAYLAND DRIVE, RICHMOND VA 23233
Marc D Oken director C/O FALFURRIAS CAPITAL PARTNERS, 100 N. TRYON STREET, SUITE 5120, CHARLOTTE NC 28202
Odonnell Kathleen M Tr Irrev Tr 1 Fbo Francis E Odonnell Jr other: former 10% owner
David C Vorhoff director C/O STAR SCIENTIFIC, INC., 801 LIBERTY WAY, CHESTER VA 23836
Christopher G Miller officer: Chief Financial Officer 801 LIBERTY WAY CHESTER VA 23836

Rock Creek Pharmaceuticals (Rock Creek Pharmaceuticals) Headlines

From GuruFocus

Star Scientific Inc. (STSI) President & COO Paul L Perito buys 20,000 Shares

By GuruFocus Research GuruFocus Editor 11-16-2009

Star Scientific Inc. (STSI) CFO Park A Iii Dodd buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 11-18-2009

Star Scientific Inc. (STSI) President & COO Paul L Perito buys 30,000 Shares

By GuruFocus Research GuruFocus Editor 11-13-2009